AtaCor Medical has announced that it has completed a US$8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-based aMoon Ventures, the financing also includes participation from a corporate partner. The investment will support the continued development of AtaCor’s revolutionary extravascular substernal cardiac pacing system.
AtaCor is developing a novel cardiac pacing method that does not require any hardware to be placed inside or onto a patient’s heart. The technology will offer a new treatment option for both transient and chronic bradycardia, including the escalating need for temporary pacing in conjunction with transcatheter aorta valve replacement (TAVR) procedures.
“We welcome our new venture partners and extend our appreciation to our earlier investors in supporting AtaCor’s goal to free patients’ hearts from unnecessary pacing hardware,” said Rick Sanghera, AtaCor’s CEO. “We are excited to accelerate development efforts and look forward to bringing this new pacing option to patients and physicians alike.”
Maria Berkman of Broadview Ventures added: “AtaCor’s technology promises to be a step change in cardiac pacing, and we look forward to working closely with the AtaCor team to support their progress toward the clinic.”
